ReviewNPJ Regenerative medicine2026
Interventions and platforms that direct lymphangiogenesis to restore physiological homeostasis and enhance immunoregulation.
Review in NPJ Regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The lymphatic system maintains physiological homeostasis through constant immunosurveillance, immune cell trafficking, and regulation of interstitial fluid flow. Lymphatic dysfunction is associated with a wide range of pathologies, including cancer metastasis and lymphedema. Aberrant lymphatic structure also contributes to chronic wounds and transplanted organ rejection. These functional and structural deficits have inspired strategies for lymphatic vasculature modulation and tissue engineering to regulate immune functions during disease and injury rehabilitation. Lymphangiogenesis-the process of lymphatic vessel growth- is central to the success of these strategies and has broad potential if harnessed for therapeutic intervention and tissue integration. Here we review the opportunities and obstacles for biomolecular pathway modulation, nanotechnology, and tissue engineering to promote or inhibit lymphangiogenesis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.